HC Wainwright Reaffirms “Buy” Rating for Oculis (NASDAQ:OCS)

Oculis (NASDAQ:OCS)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $30.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 64.65% from the company’s previous close.

Oculis Stock Up 3.2 %

OCS opened at $18.22 on Monday. The company has a market cap of $737.98 million, a PE ratio of -9.44 and a beta of -0.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. Oculis has a 1 year low of $10.50 and a 1 year high of $18.40. The firm has a 50 day moving average price of $16.35 and a 200 day moving average price of $13.84.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.